Covidien (NYSE:COV) confirmed reports that the company notched a new medtech acquisition with the stealthy purchase of Zephyr Technology, originally reported by MobiHealthNews.
Zephyr makes wireless monitors, including the consumer-focused BioHarness heart rate, breathing and posture monitor and the BioPatch continuous patient monitor. The company has raised more than $13 million since its inception in 2003, according to reports.
Neither company had announced the deal, but MobiHealthNews noted that Covidien recently tallied 3 undisclosed acquisitions in documents filed with the SEC. The trio of acquisitions were valued together at about $128 million and none were expected to have a material impact on the company’s earnings.
"While Zephyr has not made any public announcements that indicate that it has been acquired, the company did make two small changes to its ‘About’ page at the end of 2013," MobiHealthNews wrote. "It no longer lists Qualcomm Life as a partner, and it no longer refers to itself as a ‘small’ business."
